Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C42H68O13 |
Molecular Weight | 780.9815 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 21 / 21 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC(C)(C)CC[C@@]13CO[C@@]24C=C[C@]5([H])[C@@]6(C)CC[C@H](O[C@]7([H])O[C@H](C)[C@H](O)[C@H](O[C@]8([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@@](C)(CO)[C@]6([H])CC[C@@]5(C)[C@]4(C)C[C@H]3O
InChI
InChIKey=KYWSCMDFVARMPN-LCSVLAELSA-N
InChI=1S/C42H68O13/c1-21-28(46)33(55-34-31(49)30(48)29(47)22(18-43)53-34)32(50)35(52-21)54-27-10-11-37(4)23(38(27,5)19-44)8-12-39(6)24(37)9-13-42-25-16-36(2,3)14-15-41(25,20-51-42)26(45)17-40(39,42)7/h9,13,21-35,43-50H,8,10-12,14-20H2,1-7H3/t21-,22-,23-,24-,25-,26-,27+,28+,29-,30+,31-,32-,33+,34+,35+,37+,38+,39-,40+,41-,42+/m1/s1
Saikosaponin D is a triterpene saponin found in Bupleurum that exhibits antioxidative, immunomodulatory, anti-fibrotic, anti-angiogenic, anticancer, and chemopreventive activities. Saikosaponin D increases activity of superoxide dismutase, catalase, and glutathione peroxidase and decreases activity of malondialdehyde in cellular models of oxidative damage. In other in vitro models, saikosaponin D increases secretion of IL-12, maturation of dendritic cells, and proliferation of lymphocytes. Saikosaponin D inhibits SERCA, increasing intracellular Ca2+ and inducing autophagy. In vivo, this compound decreases severity of fibrosis. In embryos, saikosaponin D decreases microvessel formation. Additionally, this compound decreases tumor formation in DEN-treated animal models and suppresses expression of CEBP-β and COX-2. Saikosaponin D also induces apoptosis and activation of caspases 3 and 7 in hepatocellular carcinoma cells. Saikosaponin D is a Glucocorticoid receptor agonist. It is a COX-2 and iNOS inhibitor.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28875366 | https://www.ncbi.nlm.nih.gov/pubmed/24076136
Curator's Comment: Saikosaponin D relieves chronic mild stress induced depressive-like behavior in rats. In rats saikosaponin D significantly reduced cocaine self-administration without affecting food consumption.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
5.8 µM [IC50] | |||
Target ID: map04064 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22728095 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25268087
Mice: oral gavage of saikosaponin-d (5 mg/kg, 10 mg/kg and 20
mg/kg body weight/day).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11721431
In order to investigate the anti-proliferative effect
of saikosaponin d, ATC cells were cultured in the
presence of various concentrations of saikosaponin-d
(5 umol/L, 10 umol/L, 15 umol/L and 20 umol/L).
MTT assay showed that saikosaponin-d treatment significantly
inhibited the proliferation of ARO, 8305C and SW1736 in a time- and dose-dependent manner.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
20874-52-6
Created by
admin on Fri Dec 15 18:11:51 GMT 2023 , Edited by admin on Fri Dec 15 18:11:51 GMT 2023
|
PRIMARY | |||
|
UR635J3F00
Created by
admin on Fri Dec 15 18:11:51 GMT 2023 , Edited by admin on Fri Dec 15 18:11:51 GMT 2023
|
PRIMARY | |||
|
107793
Created by
admin on Fri Dec 15 18:11:51 GMT 2023 , Edited by admin on Fri Dec 15 18:11:51 GMT 2023
|
PRIMARY | |||
|
DTXSID301317467
Created by
admin on Fri Dec 15 18:11:51 GMT 2023 , Edited by admin on Fri Dec 15 18:11:51 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD